Related Experiment Videos
Cytoreductive nephrectomy: A medical oncologist's perspective.
Nazli Dizman1, Manuel Caitano Maia1, Sumanta K Pal1
1Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA.
Urologic Oncology
|October 18, 2017
Summary
Cytoreductive nephrectomy (CN) benefits metastatic renal cell carcinoma patients. While targeted therapies are now standard, ongoing studies are needed to confirm CN
Area of Science:
- Oncology
- Surgical Oncology
- Nephrology
Background:
- Cytoreductive nephrectomy (CN) was established in the cytokine era with interferon therapy.
- Systemic therapy for metastatic renal cell carcinoma (mRCC) has shifted to targeted therapies.
- Retrospective data suggest CN benefits are maintained in the targeted therapy era.
Purpose of the Study:
- To evaluate the role of cytoreductive nephrectomy (CN) in the current era of targeted therapy for metastatic renal cell carcinoma (mRCC).
- To discuss ongoing prospective studies assessing CN.
- To propose new strategies for evaluating CN amidst evolving treatment landscapes.
Main Methods:
- Review of existing literature on cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC).
- Discussion of retrospective data supporting CN in the targeted therapy era.
- Analysis of ongoing prospective clinical trials for CN in mRCC.
Main Results:
- The role of CN was established using older cytokine-based therapies.
- Current retrospective data suggest CN may still benefit mRCC patients receiving targeted therapies.
- Prospective evidence is lacking due to inherent biases in retrospective studies.
Conclusions:
- The benefit of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) requires further validation in the era of targeted therapies.
- Ongoing prospective studies are crucial to definitively establish the role of CN.
- Novel evaluation strategies are needed to assess CN in the evolving mRCC treatment paradigm.